Neuberger Berman Group
AMPH icon

Neuberger Berman Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Neuberger Berman Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,374,125
Closed -$51M – 1977
2024
Q4 		$51M Sell
1,374,125
-240,963
-15% -$11M 0.04% 438
2024
Q3 		$78.4M Sell
1,615,088
-7,521
-0.5% -$330K 0.06% 343
2024
Q2 		$64.9M Sell
1,622,609
-37,208
-2% -$1.54M 0.05% 363
2024
Q1 		$72.9M Sell
1,659,817
-1,726,187
-51% -$89.2M 0.06% 345
2023
Q4 		$209M Buy
3,386,004
+1,898,025
+128% +$99.7M 0.09% 274
2023
Q3 		$68.4M Sell
1,487,979
-2,305
-0.2% -$126K 0.06% 335
2023
Q2 		$85.6M Buy
1,490,284
+1,059,032
+246% +$46.9M 0.08% 305
2023
Q1 		$16.2M Buy
+431,252
New +$14.1M 0.02% 656

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's AMPH Position: Q1 2025 in Review

Neuberger Berman Group sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 1,374,125 shares — an estimated $51M sold.

Neuberger Berman Group first reported a position in AMPH in Q1 2023 and held it in 8 quarters. The position peaked at $209M in Q4 2023. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • Neuberger Berman Group reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 1,374,125 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $51M.
  • Neuberger Berman Group first reported a position in Amphastar Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Neuberger Berman Group's Amphastar Pharmaceuticals position peaked at $209M in Q4 2023.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Neuberger Berman Group's 13F filing for Q1 2025, filed 13 May 2025.